^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MRDx BCR-ABL Test

    Company:
    Icon plc
    Type:
    FDA Approved
    Evidence Level:
    Sensitive: B - Late Trials

    [BCR-ABL1 fusion-Chronic Myeloid Leukemia-nilotinib]

    Source:
    J Cancer Res Clin Oncol
    Test:

    MRDx BCR-ABL Test

    Title:
    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
    Excerpt:
    Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS ≤ 0.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.
    DOI:
    10.1007/s00432-018-2604-x
    Trial ID:
    ENESTFreedom